clinical trial · NCT07843472
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
Obesity or OverweightCardiovascular DiseasePetrelintidePlacebo
brief summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
started
Sep 30, 2026
primary completion
Jul 28, 2030
completion
Oct 6, 2030
last updated
Nov 16, 2026
official title
A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol